Peps
What is Teriparatide?
Teriparatide is a parathyroid-hormone-related medicine used in osteoporosis care. Fracture reduction is a more direct clinical outcome than a bone marker alone.
Biological role or research focus
Parathyroid-hormone-related bone formation.
The relevant clinical setting is osteoporosis with high fracture risk, not broad performance enhancement.
Role reference: MedlinePlus · Teriparatide ↗
Names you may encounter
Forteo
Search terms can include brands, combinations, or historical names. They are not automatic product equivalents.
- Class / identity
- PTH(1–34) analogue
- Main research area
- Bone formation and fracture prevention
- Evidence featured
- Human randomized trial
- Source check
- October 4, 2026
Source: MedlinePlus · Teriparatide ↗
Molecular structure
Mechanism & research rationale
Its therapeutic action promotes bone formation and increases bone strength and density. Those actions are studied in a defined bone-disease context.
Source: MedlinePlus · Teriparatide ↗
Clinical uses & product context
The medication reference describes osteoporosis treatment in selected patients. The trial below concerns postmenopausal women with previous vertebral fractures, a population with substantial baseline risk.
Source: MedlinePlus · Teriparatide ↗
What does the evidence show?
Selected published evidence, with the population, findings, and limits kept together. These original summaries draw on publication abstracts; they are not a systematic review.
Human randomized trial · 2001
Fracture Prevention Trial
Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis.
- Population / model
- 1,637 postmenopausal women with prior vertebral fractures.
- Study design
- Two PTH(1–34) groups versus placebo; median observation 21 months.
- Main finding
- New vertebral fractures occurred in 14% with placebo versus 5% and 4% in the active groups. Bone mineral density also increased.
- Limits & context
- This is fracture-prevention evidence in osteoporosis. It does not establish accelerated healing of every sports injury or benefit in people with normal bone density.
Read the original paper for methods, adverse events, funding, and conflicts of interest. Publisher access may require a subscription.
Further reading · 4 additional publication links
Exact-name PubMed search checked 2026-10-04. These records have not been appraised. A name match can include related compounds, combinations, or other formulations; it does not establish safety or benefit.
Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial. ↗
Lancet (London, England) · 2015 Sep 19 · Journal Article, Randomized Controlled Trial, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
Read available full text ↗
Effects of teriparatide versus alendronate for treatment of postmenopausal osteoporosis: A meta-analysis of randomized controlled trials. ↗
Medicine · 2017 May · Comparative Study, Journal Article, Meta-Analysis, Systematic Review
Read available full text ↗
Teriparatide. ↗
· 2012 · Review
PTH1 receptor agonists for fracture risk: a systematic review and network meta-analysis. ↗
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2025 Jun · Journal Article, Network Meta-Analysis, Systematic Review
Read available full text ↗
New editorial updates
New source discoveries
Links appear automatically. Unreviewed discoveries are not verified medical findings.
Safety & precautions
Key precautions
Elevated calcium, kidney stones, dizziness, and specific bone-cancer risk factors require review. Prior skeletal radiation and other bone disorders can affect suitability.
Source: MedlinePlus · Teriparatide ↗
This is not a complete list of contraindications, interactions, or adverse effects. Medicine labels apply to specific products and indications; research-use listings are not interchangeable with approved medicines.
What are people discussing?
No editorial transcript note has been reviewed for this profile yet. Below are the matching video records available for exploration; title and caption matches are not verified claims.
Watch the source discussions
1 matching video records · 1 with captions indexed.
Across the full library, 30 caption files are indexed from 20,199 inventoried videos. Most transcripts remain unreviewed. Select a thumbnail or timestamp to watch inside PepsRadar. Thumbnail images load from YouTube.
Peptide Of The Week
Telehealth vs Research Peptides: The Truth Nobody Tells You | Peptide of the Week Q&A #61 ↗
Captions indexed · Automatic matches need review
Sources & supplier listings
Listings are grouped by the vendor’s stated identity. Blends and modified derivatives are labeled separately. Inclusion is not a quality assessment or an endorsement.
We have not added a supplier for this profile. Missing products and coded listings are not filled with guesses.
Catalog checked 2026-10-04. Seller listings retain their stated intended use. Shops covered: BioLongevity Labs, BioLongevity Supplements, American Peptides, PSPeptides. This is not a market-wide comparison. Affiliate participation does not determine evidence or editorial coverage.
Questions worth asking
- Which indication and formulation does the source describe?
- Does the video make a broader claim than the source supports?
- The relevant clinical setting is osteoporosis with high fracture risk, not broad performance enhancement.
- What adverse effects, uncertainty, and conflicts of interest does the original source report?
Frequently asked questions
Does fracture prevention prove faster healing of an existing injury?
No. Preventing a new fracture and healing an existing one are different clinical questions.
Source: MedlinePlus · Teriparatide ↗
Can the trial results be applied to people with normal bone density?
Not directly. Baseline risk and the condition being treated strongly affect benefit and harm.
References & editorial record
- MedlinePlus · Teriparatide ↗
- Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. ↗
Source notes checked 2026-10-04. Original PepsRadar summaries. Not reviewed by a medical professional. Topic grouping is editorial navigation, not a treatment recommendation. Video notes specify which excerpts were reviewed; no full transcripts are published.